



Kuvan® (sapropterin) – First-time generic

- On October 1, 2020, Par launched [AB-rated](#) generic versions of BioMarin's [Kuvan \(sapropterin\)](#) tablet and oral packets.
- Kuvan is approved to reduce blood phenylalanine levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia due to tetrahydrobiopterin-responsive phenylketonuria.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.